NGM
Income statement / Annual
Last year (2023), NGM Biopharmaceuticals, Inc.'s total revenue was $4.42 M,
a decrease of 92.02% from the previous year.
In 2023, NGM Biopharmaceuticals, Inc.'s net income was -$142.38 M.
See NGM Biopharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$4.42 M |
$55.33 M |
$77.88 M |
$87.37 M |
$103.54 M |
$108.67 M |
$77.14 M |
$85.59 M |
| Cost of Revenue |
$2.22 M
|
$5.98 M
|
$7.90 M
|
$163.97 M
|
$129.25 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.20 M
|
$49.35 M
|
$69.98 M
|
-$76.60 M
|
-$25.71 M
|
$108.67 M
|
$77.14 M
|
$85.59 M
|
| Gross Profit Ratio |
0.5
|
0.89
|
0.9
|
-0.88
|
-0.25
|
1
|
1
|
1
|
| Research and Development Expenses |
$112.01 M
|
$181.07 M
|
$161.71 M
|
$163.97 M
|
$129.25 M
|
$95.71 M
|
$79.74 M
|
$82.11 M
|
| General & Administrative Expenses |
$37.84 M
|
$40.52 M
|
$36.87 M
|
$27.23 M
|
$23.63 M
|
$17.27 M
|
$14.83 M
|
$11.85 M
|
| Selling & Marketing Expenses |
-$1.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$36.74 M
|
$40.52 M
|
$36.87 M
|
$27.23 M
|
$23.63 M
|
$17.27 M
|
$14.83 M
|
$11.85 M
|
| Other Expenses |
-$234,000.00
|
-$132,000.00
|
-$60,000.00
|
-$593,000.00
|
-$147,000.00
|
$199,000.00
|
-$152,000.00
|
$133,000.00
|
| Operating Expenses |
$148.74 M
|
$221.58 M
|
$198.58 M
|
$191.20 M
|
$152.88 M
|
$112.98 M
|
$94.57 M
|
$93.95 M
|
| Cost And Expenses |
$150.96 M
|
$221.58 M
|
$198.58 M
|
$191.20 M
|
$152.88 M
|
$112.98 M
|
$94.57 M
|
$93.95 M
|
| Interest Income |
$9.32 M
|
$3.71 M
|
$420,000.00
|
$1.94 M
|
$6.69 M
|
$3.62 M
|
$2.36 M
|
$1.81 M
|
| Interest Expense |
$0.00
|
$3.71 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.22 M
|
$4.04 M
|
$6.09 M
|
$6.56 M
|
$7.61 M
|
$7.22 M
|
$6.44 M
|
$3.53 M
|
| EBITDA |
-$144.33 M |
-$166.25 M |
-$120.70 M |
-$103.83 M |
-$49.34 M |
$2.91 M |
-$10.98 M |
-$4.83 M |
| EBITDA Ratio |
-32.68
|
-3
|
-1.55
|
-1.19
|
-0.48
|
0.03
|
-0.14
|
-0.06
|
| Operating Income Ratio |
-33.18
|
-3
|
-1.55
|
-1.19
|
-0.48
|
-0.04
|
-0.23
|
-0.1
|
| Total Other Income/Expenses Net |
$4.17 M
|
$3.58 M
|
$360,000.00
|
$1.35 M
|
$6.55 M
|
$3.82 M
|
$2.21 M
|
$1.94 M
|
| Income Before Tax |
-$142.38 M
|
-$162.67 M
|
-$120.34 M
|
-$102.49 M
|
-$42.80 M
|
-$493,000.00
|
-$15.22 M
|
-$6.42 M
|
| Income Before Tax Ratio |
-32.23
|
-2.94
|
-1.55
|
-1.17
|
-0.41
|
-0
|
-0.2
|
-0.08
|
| Income Tax Expense |
$0.00
|
-$3.58 M
|
-$6.51 M
|
-$8.49 M
|
-$14.30 M
|
$3.82 M
|
-$1.06 M
|
$500,000.00
|
| Net Income |
-$142.38 M
|
-$159.09 M
|
-$113.83 M
|
-$93.99 M
|
-$28.50 M
|
-$493,000.00
|
-$14.16 M
|
-$6.92 M
|
| Net Income Ratio |
-32.23
|
-2.88
|
-1.46
|
-1.08
|
-0.28
|
-0
|
-0.18
|
-0.08
|
| EPS |
-1.73 |
-1.99 |
-1.48 |
-1.37 |
-0.57 |
-0.0076 |
-0.26 |
-0.13 |
| EPS Diluted |
-1.73 |
-1.99 |
-1.48 |
-1.37 |
-0.57 |
-0.0076 |
-0.26 |
-0.13 |
| Weighted Average Shares Out |
$82.50 M
|
$79.95 M
|
$77.09 M
|
$68.48 M
|
$50.30 M
|
$64.99 M
|
$53.65 M
|
$53.65 M
|
| Weighted Average Shares Out Diluted |
$82.50 M
|
$79.95 M
|
$77.09 M
|
$68.48 M
|
$50.30 M
|
$64.99 M
|
$53.65 M
|
$53.65 M
|
| Link |
|
|
|
|
|
|
|
|
